SCHEMBL10244860

SCHEMBL10244860

COC(=O)NCCNC(C)c1ccc(O)c(C)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 1/20 0.35
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
TSHR P16473 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32
KDR P35968 1/20 0.31
PDCD1LG2 Q9BQ51 3/20 0.31
CD274 Q9NZQ7 3/20 0.31
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243936 0.80 CA12 (0.40) TSHRMEN1KMT2AMAPT
SCHEMBL10244507 0.79 MAPT (0.41) MEN1KMT2AHTTMAPTNPC1
SCHEMBL10243952 0.79 POLB (0.51) TSHRHTTALDH1A1SMN1; SMN2LMNA
SCHEMBL10244519 0.77 MTNR1A (0.43) TSHRMEN1KMT2AHTTMAPT
SCHEMBL10244889 0.74 CA12 (0.40) RRM1TSHREPHX1MAPTRAB9A
SCHEMBL10244611 0.73 HPGD (0.49) HTTSMN1; SMN2LMNA
SCHEMBL10244285 0.73 ESR1 (0.42) RRM1SLC6A2SLC6A4SLC6A3CD274
SCHEMBL10244235 0.72 TSHR (0.43) SLC6A2SLC6A4SLC6A3TSHRHTT
SCHEMBL10244323 0.72 SLC22A3 (0.51) TSHRLMNA
SCHEMBL10243808 0.70 HCRTR1 (0.50) TSHRKMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RRM1 3124/4885SLC6A2 4677/4885SLC6A4 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.